Symrise AG
5-year stock timeline
As of 2026-05-20, Symrise (SY1.XETRA) trades at 76.22. Here's a concise 5-year timeline (2020–2026) tracking material company and stock events, how investor narrative shifted, and the main technical chart phases.
Major events
2020 — Symrise delivered organic sales growth of roughly 2.7% and maintained profitability targets despite pandemic pressure. A criminal cybersecurity attack in mid-December disrupted operations and weighed on Q4 sales.
Late 2020 into 2021 — The group acquired Sensient's fragrance and aroma business (announced late 2020, integrated through 2021) and gained promotion to the German DAX in September 2021. Both moves materially expanded scale and market visibility.
2024–2025 — Management reiterated medium-term ambitions around a ~20% EBITDA margin while reporting robust organic growth in early 2025. The Supervisory Board completed the Executive Board at five members as part of governance and management adjustments in 2025.
Investor perception
Early 2020s — Investors increasingly viewed Symrise as a resilient, defensive compounder. The company preserved growth and profitability through pandemic headwinds and the operational disruption of late 2020.
Post-deal and DAX entry (2021) — The narrative shifted toward growth-through-M&A and strategic consolidation in fragrances and aroma chemicals as scale and visibility rose following the Sensient transaction and index promotion.
By 2024–25 — Market focus narrowed to margin sustainability and sensitivity to currency and operational headwinds. The question became whether Symrise could deliver margin targets while sustaining above-market organic growth.
Technical phases
2020 — The stock experienced a pandemic-era drawdown followed by recovery as operational resilience became apparent. The December cyber incident coincided with short-term weakness before stabilization.
2021 — Acquisition announcements and DAX inclusion correlated with renewed investor interest and a multi-month uptrend as the company's scale and visibility improved.
2022–mid-2024 — Price action turned more volatile and often rangebound amid macro and currency headwinds on reported results. 2024–early 2025 displayed renewed upside as organic growth strengthened and margin guidance held, bringing the series to the current 76.22 level.
Key risks and downside factors
Symrise competes in a concentrated global market for flavours, fragrances and specialty ingredients, where a handful of large players—Givaudan and IFF chief among them—sit alongside several capable regional competitors. Success here demands scale, serious R&D investment (biotech and precision fermentation included), and credible sustainability positioning. That combination creates persistent margin pressure and forces continuous capital spending and innovation just to stay competitive. Regulatory oversight and antitrust scrutiny loom as occasional headwinds, while raw material costs and supply chain instability introduce real earnings volatility that investors need to watch.
- Raw-material price swings and concentrated agricultural supply chains can compress margins and strain working capital.
- Global consolidation among the major players—Givaudan, IFF, DSM‑Firmenich—has intensified competition and created real pressure on both pricing and market share [8][1].
- Regulatory and antitrust investigations across the fragrance and flavor industry create real exposure to fines and remediation costs.
- Biotech-derived ingredients and natural credentials demand sustained R&D spending, with real risk that slower movers end up with obsolete products on their hands [8][4].
Competitive landscape
Symrise operates in a flavors, fragrances and specialty-ingredients market where scale matters. Givaudan and IFF dominate globally, with the DSM-Firmenich combination adding weight to that tier. Below them, regional and niche players like MANE, Takasago and Döhler hold ground in specialty segments. The competitive landscape is shifting—sustainability demands, biotech capabilities and sourcing constraints are becoming differentiators rather than afterthoughts. The company faces real structural headwinds. Larger competitors can absorb margin compression better. Raw materials and supply chains remain volatile. Regulatory pressure and clean-label reformulation work costs money. And customer concentration means revenue can swing based on what a handful of accounts decide to do.
| Company | Ticker |
|---|---|
| Givaudan SA | GIVN.SIX |
| International Flavors & Fragrances Inc. | IFF.NYSE |
| Sensient Technologies Corporation | SXT.NYSE |
| McCormick & Company, Incorporated | MKC.NYSE |
Private competitors
- Firmenich
- MANE
- Takasago
- Döhler
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Symrise AG
Relative Performance vs Benchmarks
| Period | Symrise AG | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +1.12% | +0.88% | -2.41% |
| 3M | +3.41% | +5.68% | -4.08% |
| 6M | +9.40% | +3.41% | -2.57% |
| 1Y | -25.30% | -27.13% | -50.48% |
| 3Y | -25.20% | -75.58% | -107.34% |
| 5Y | -25.21% | -83.76% | -114.54% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 28.1 | 1.7 | 2.8 | 7.5 |
| 1Y ago | 30.5 | 2.9 | 3.7 | 16.3 |
| 3Y ago | 39.7 | 2.5 | 4.2 | 35.3 |
| 5Y ago | 30.7 | 2.7 | 5.8 | 16.6 |
Frequently Asked Questions
Where is the Symrise AG stock traded?
What does Symrise AG do?
What are the key metrics for SY1.XETRA?
How has Symrise AG's stock price performed?
How is SY1.XETRA valued?
Does SY1.XETRA pay dividends?
What are the key risks when investing in SY1.XETRA?
- Raw-material price swings and concentrated agricultural supply chains can compress margins and strain working capital.
- Global consolidation among the major players—Givaudan, IFF, DSM‑Firmenich—has intensified competition and created real pressure on both pricing and market share [web:8][web:1].
- Regulatory and antitrust investigations across the fragrance and flavor industry create real exposure to fines and remediation costs.
- Biotech-derived ingredients and natural credentials demand sustained R&D spending, with real risk that slower movers end up with obsolete products on their hands [web:8][web:4].
Who are the main competitors of Symrise AG?
- Givaudan SA (GIVN.SIX)
- International Flavors & Fragrances Inc. (IFF.NYSE)
- Sensient Technologies Corporation (SXT.NYSE)
- McCormick & Company, Incorporated (MKC.NYSE)
When does Symrise AG report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.25 EUR | 1.65% | 1.25% |
| 2025 | 1.20 EUR | 1.14% | |
| 2024 | 1.10 EUR | 1.08% | |
| 2023 | 1.05 EUR | 0.97% | |
| 2022 | 1.02 EUR | 0.93% | |
| 2021 | 0.97 EUR | 0.89% | |
| 2020 | 0.95 EUR | 0.98% | |
| 2020 | 0.95 EUR | 1.02% | |
| 2019 | 0.90 EUR | 1.04% | |
| 2018 | 0.88 EUR | 1.23% | |
| 2017 | 0.85 EUR | 1.34% | |
| 2016 | 0.80 EUR | 1.40% | |
| 2015 | 0.75 EUR | 1.32% | |
| 2014 | 0.70 EUR | 1.84% | |
| 2013 | 0.65 EUR | 1.99% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 4.93B | 5.00B | 4.73B | 4.62B | 3.83B |
| Operating income (EBIT) | 609.30M | 717.80M | 559.36M | 503.98M | 558.96M |
| Net income | 249.30M | 478.20M | 340.47M | 280.01M | 374.92M |
| Free cash flow | 521.05M | 667.49M | 449.31M | 109.94M | 347.40M |
| Total assets | 8.11B | 8.32B | 7.85B | 7.78B | 6.64B |
| Equity | 3.72B | 3.98B | 3.63B | 3.55B | 3.19B |
| Net debt | 1.60B | 1.84B | 2.17B | 2.23B | 1.35B |
PWP Leeway UG (haftungsbeschränkt)
